Organization
Salarius Pharmaceuticals
3 clinical trials
Clinical trial
Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select SarcomasStatus: Active (not recruiting), Estimated PCD: 2025-09-01
Clinical trial
A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SP-3164 in Patients With Relapsed/Refractory Non-Hodgkin's LymphomaStatus: Not yet recruiting, Estimated PCD: 2025-08-15
Clinical trial
A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)Status: , Estimated PCD: 2025-12-01